France · Who invested in Bionyra Pharma?
Bionyra Pharma's investors include Sofinnova Partners, Jeito Capital, Apollo, Sanofi and VIVES Partners, and 3 more on record. Sofinnova Partners led its latest round.
France · Series A startup
Who invested in Bionyra Pharma
One round we have observed, with the 8 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Raised 4 months ago
Follow Bionyra Pharma and see its new rounds in your feed. Start following
Funding summaryUpdated 5 Nov 2026
$165Mraised across 1 round since 2026, from 2 sources
- Latest round
- Series A, $165MJun 2026
- Led by
- Sofinnova Partners and Jeito Capital
- Investors
- 8 (2 led)
The rounds
- Jun 2026Series A$165M
Sofinnova PartnersLead
Jeito CapitalLead
Apollo
Sanofi
VIVES Partners
Apollo Health Ventures- Arkin Bio
Sixty Degree Capital
Reported by Ventureburn and 1 other
Everyone who backed them
Arkin BioInvestment firm1round
Missing a round, or an investor who was in one? Tell us.
Quick answers about Bionyra Pharma
How much has Bionyra Pharma raised?
Bionyra Pharma has raised $165M across 1 round since 2026.
When did Bionyra Pharma last raise?
Bionyra Pharma's most recent round was a Series A of $165M in Jun 2026, led by Sofinnova Partners.
What was Bionyra Pharma's biggest round?
Its most recent round, $165M in Jun 2026, is also its largest on record.
Who backed Bionyra Pharma first?
Bionyra Pharma's first round on record, in Jun 2026, was backed by Sofinnova Partners, Jeito Capital and Apollo and 5 others.
What stage is Bionyra Pharma at?
Bionyra Pharma's latest named round is a Series A, in Jun 2026.
Where is Bionyra Pharma based?
Bionyra Pharma is based in France.
Who led Bionyra Pharma's rounds?
Sofinnova Partners led the Series A in 2026.
Companies like Bionyra Pharma
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.